CV Sciences Inc (CVSI)

[SpaceLady]

Thank you, Sleuth,
The candidates look to be supportive of CBD and MJ.

Norman Sharpless (Ned), current director of the National Cancer Institute (NCI) is another contender for Gottlieb’s position. In the 1980’s Ned coauthored articles that discussed marijuana's euphorigenic properties in rats. Today, the NCI’s website admits, “cannabis has been used for medicinal purposes for thousands of years.. promoted for reported analgesic, sedative, anti-inflammatory, antispasmodic, and anticonvulsant effects.” Their website even states that physicians were the principal opponents of the Marihuana Tax Act 1937 which made cannabis more difficult to procure. As many cancer patients are users of medicinal marijuana and NCI’s website seems to recognize the benefits of both THC and CBD, Ned Sharpless would likely clear the way for healthcare providers to research and develop cannabis medication.

Next on the list is Brett Giroir, Assistant Secretary for Health in the U.S. Health and Human Services Department, FDA’s parent agency. Giroir has been extremely public about removing CBD from DEA’s Schedule 1 status writing that “CBD and its salts [should] be controlled in Schedule V of the Controlled Substances Act." Schedule V drugs demonstrate medical values and are deemed unlikely to cause harm, abuse, or addiction.

Janet Woodcock is another prospect for the position. Currently heading the FDA’s Center for Drug Evaluation and Research CDER, Woodcock has rejected proposals by Drug Watch International to place marijuana on another list of restricted substances. She is already part of the team that is working with companies to fast track effective medications including those containing CBD.

So why, Tony Owusu? Why do you think that Gottlieb’s resignation is cause for cannabis investors to panic? Does it really justify a massive selloff like we saw today? Is it really any cause for concern? The FDA already admits that marijuana has been known for medical use for over 3,000 years despite what the DEA says. Marijuana has unjustly been classified as Schedule 1, 49 years ago. Perhaps 50 years is enough. It is more than likely that next head of the FDA that replaces Gottlieb will not only help fast track cannabis medications but also ease most restrictions on CBD products.